Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2006 by FDA Office of Orphan Products Development.
Recruitment status was  Active, not recruiting
Study NCT00086203   Information provided by FDA Office of Orphan Products Development

First Received on June 28, 2004.   Last Updated on August 2, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Lymphocytic Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Point Therapeutics
FDA Office of Orphan Products Development


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services